Obinutuzumab in two patients suffering from immune‐mediated thrombotic thrombocytopenic purpura intolerant to rituximab
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25583
Abstract: lary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia. 2007;21(11):2394-2396. 5. Krysiak K, Christopher MJ, Skidmore ZL, et al. A… read more here.
Keywords: obinutuzumab two; myeloid leukemia; chronic myeloid; philadelphia chromosome ... See more keywords
Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25648
Abstract: Despite the advances in the management of Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) with the introduction of tyrosine kinase inhibitors (TKIs), relapses remain challenging. We reviewed clinical data from adult patients with Ph + ALL who… read more here.
Keywords: first relapse; positive acute; lymphoblastic leukemia; acute lymphoblastic ... See more keywords
Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2680
Abstract: In adult patients with relapsed or refractory (R/R) Philadelphia chromosome‐negative (Ph‐negative) B‐cell presursor acute lymphoblastic leukemia (BCP‐ALL), complete remission (CR) and overall survival (OS) rates are poor. We analyzed treatment outcomes and prognostic factors for… read more here.
Keywords: cell; blinatumomab; first salvage; philadelphia chromosome ... See more keywords
Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31082
Abstract: Health‐related quality of life (HRQOL) in patients with chronic‐phase chronic myeloid leukemia (CML) is important because of the requirement for long‐term treatment. This study assessed HRQOL in bosutinib‐treated patients with Philadelphia chromosome–positive CML and resistance… read more here.
Keywords: long term; myeloid leukemia; chronic myeloid; chromosome positive ... See more keywords
When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32565
Abstract: Over the past several years, there has been substantial progress made in the approach to treating adults with relapsed/ refractory B-cell acute lymphoblastic leukemia (B-ALL). Previously, the only options available outside the context of a… read more here.
Keywords: relapsed refractory; trial; blinatumomab; philadelphia chromosome ... See more keywords
Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33529
Abstract: The achievement of a 3‐month complete molecular response (CMR) is a major prognostic factor for survival in patients with Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukemia (ALL). However, 25% of patients relapse during therapy with tyrosine… read more here.
Keywords: molecular response; positive acute; patients philadelphia; complete molecular ... See more keywords
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-019-0603-z
Abstract: With the introduction of tyrosine kinase inhibitors (TKIs) in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the prognosis of patients has improved dramatically. Currently, the standard of care in the frontline setting… read more here.
Keywords: positive acute; treatment; lymphoblastic leukemia; chromosome positive ... See more keywords
New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-017-0372-3
Abstract: Purpose of ReviewTo review recent studies that address important questions regarding the treatment of Philadelphia chromosome-positive ALL.Recent FindingsLess intensive non-myelosuppressive induction approaches can produce comparable anti-leukemic responses with less toxicity. Second-generation tyrosine kinase inhibitors (TKIs)… read more here.
Keywords: new treatment; treatment strategies; chromosome positive; philadelphia chromosome ... See more keywords
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia research"
DOI: 10.1016/j.leukres.2018.03.010
Abstract: BACKGROUND AND OBJECTIVE The standardization of treatment of older adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) is challenging, especially in the age range of 55-65 years. This study aimed to compare intensive,… read more here.
Keywords: pediatric inspired; chromosome negative; negative acute; philadelphia chromosome ... See more keywords
Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant
Sign Up to like & getrecommendations! Published in 2019 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-019-0585-2
Abstract: Although cytogenetic abnormalities at diagnosis are recognized as an important prognostic factor in patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL), the prognostic impact has not been evaluated in allogeneic stem cell transplant (allo-SCT)… read more here.
Keywords: cytogenetic abnormalities; group; patients philadelphia; philadelphia chromosome ... See more keywords
Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of adolescent and young adult oncology"
DOI: 10.1089/jayao.2021.0200
Abstract: Philadelphia chromosome positive (Ph+) B cell acute lymphoblastic leukemia (ALL) is extremely rare in pregnancy. Although the use of tyrosine kinase inhibitors (TKIs) has significantly improved outcomes of patients with Ph+ ALL, its use during… read more here.
Keywords: chromosome positive; philadelphia chromosome; lymphoblastic leukemia; pregnancy ... See more keywords